Fig. 2: Approximate mean antidepressant responses in the literature versus responses to sertraline alone and sertraline with celecoxib observed by Majd et al., 2015. | Cell Death Discovery

Fig. 2: Approximate mean antidepressant responses in the literature versus responses to sertraline alone and sertraline with celecoxib observed by Majd et al., 2015.

From: The role of immunomodulators in treatment-resistant depression: case studies

Fig. 2

A bar chart showing the percentage response rate, remission rate and non-response rate to antidepressant treatment. Responses to three drug treatments are compared: the average first-line selective serotonin reuptake inhibitor (SSRI) (numbers derived from analysis of the wider literature [1, 22, 23], shown on the left, sertraline in drug-naive women (data taken from [58]), shown in the centre, and sertraline in combination with celecoxib in drug-naive women [58], shown on the right. The addition of celecoxib to SSRI treatment dramatically increases the percentage rate of response (100% taking celecoxib vs 75–78% taking placebo/nothing) and rate of remission (57% taking celecoxib vs 11–25% taking placebo/nothing). This provides evidence as to the efficacy of celecoxib as an adjunctive treatment and suggests it may actively target the treatment-resistant depression subtype.

Back to article page